Abivertinib

also known as AC0010 · AC0010MA · A-610MA · A610 · ABIVERTINIB MALEATE · Abivertinib maleate dihydrate · Ac0010 maleate dihydrate · ACEA-100610MA · +6 more

Small molecule targets BTK, EGFR via inhibition

Developed for: non-small cell lung carcinoma · COVID-19 · B-cell non-Hodgkin lymphoma · metastatic prostate carcinoma
Investigated by: Hangzhou ACEA Pharmaceutical Research Co., Ltd. · Guangdong Provincial People's Hospital · Sorrento Therapeutics, Inc. · Acea Bio (Hangzhou) Co., Ltd. · ACEA Therapeutics, Inc. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
+3 more
· Chinese Thoracic Oncology Group · Guangdong Association of Clinical Trials · Sun Yat-sen University

Trials 13

today NCT05361915 · Ph 2 NCT04528667 · Ph 2 NCT04440007 · Ph 2 NCT03856697 · Ph 3 NCT03058094 · Ph 3 NCT03574402 · Ph 2 NCT03300115 · Ph 2 NCT03060850 · Ph 1 NCT03053219 · Ph 1 NCT03001609 · Ph 1 NCT02448251 · Ph 1 NCT02330367 · Ph 1/2 NCT02274337 · Ph 1/2

20152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 14 trials
Phase 1	NCT03060850	Mar 2017 → Dec 2019	B-cell non-Hodgkin lymphoma	Hangzhou ACEA Pharmaceutical Research Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT03053219	Nov 2016 → Jul 2018	non-small cell lung carcinoma	Hangzhou ACEA Pharmaceutical Research Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03001609	Nov 2016 → Aug 2017	non-small cell lung carcinoma	Hangzhou ACEA Pharmaceutical Research Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02448251	May 2015 → Oct 2019	non-small cell lung carcinoma	ACEA Therapeutics, Inc.	Terminated	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02330367	Jan 2015 → Dec 2022	non-small cell lung carcinoma	Hangzhou ACEA Pharmaceutical Research Co., Ltd.	Unknown	No outcome recorded
Phase 1/2	NCT02274337	Sep 2014 → Jun 2017	non-small cell lung carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 25 trials · 1 met primary
Phase 2	NCT05361915	Sep 2025 → Jan 2028	metastatic prostate carcinoma	Sorrento Therapeutics, Inc.	Suspended	No outcome recorded
Phase 2	NCT04528667	Jan → Aug 2021	COVID-19	Sorrento Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT04440007	Oct 2020 → Jul 2021	COVID-19	Sorrento Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT03574402	Jul 2018 → Dec 2022	non-small cell lung carcinoma	Guangdong Association of Clinical Trials	Unknown	Met primary
Phase 2	NCT03300115	May 2017 → Jun 2019	non-small cell lung carcinoma	Hangzhou ACEA Pharmaceutical Research Co., Ltd.	Unknown	No outcome recorded
Phase 32 trials
Phase 3	NCT03856697	Mar 2019 → Mar 2022	non-small cell lung carcinoma	Hangzhou ACEA Pharmaceutical Research Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT03058094	Dec 2018 → Dec 2019	non-small cell lung carcinoma	Hangzhou ACEA Pharmaceutical Research Co., Ltd.	Withdrawn	No outcome recorded

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

Field	Value	Cited text
Known as	Abivertinib	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03856697 ↗ 2 NCT04440007 ↗ NCT05361915 ↗
Known as	A-610MA	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	A610	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	ABIVERTINIB MALEATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	Abivertinib maleate dihydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	AC0010	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02330367 ↗ 5 NCT03001609 ↗ NCT03058094 ↗ NCT03300115 ↗ NCT03053219 ↗ NCT02274337 ↗
Known as	Ac0010 maleate dihydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	AC0010MA	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02448251 ↗ 1 NCT03060850 ↗
Known as	ACEA-100610MA	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	ACEA100610	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	Avitinib	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	Avitinib Maleate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03574402 ↗
Known as	EX-ACEA-0010MA	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	EX-ACEA0010	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865 ↗
Known as	STI-5656	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04528667 ↗
Action	Inhibit	“selectively suppress the activities of EGFR tyrosine kinase phosphorylation” NCT02274337 ↗
Modality	Small molecule	“AC0010 is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI)” NCT02330367 ↗
Route	Oral	“oral AC0010” NCT02330367 ↗
Target	EGFR	“selectively suppress the activities of EGFR tyrosine kinase phosphorylation” NCT02274337 ↗